Molika Ashford

NEW YORK – With new real-world evidence reinforcing the predictive ability of its MammaPrint risk assessment test, Agendia said this week that it

NEW YORK – Based on results of an analysis of existing public data on multi-cancer screening tests, a team from RTI International, the University

Premium Save for later NEW YORK – Quest Diagnostics-owned liquid biopsy developer Haystack Oncology is expecting in the next year to bring a new wealth of data supporting the ability of its circulating tumor DNA technology for use in minimal/molecular residual disease (MRD) detection across a variety of indications, especially those where its higher sensitivity may give it a boost over other technologies.

Sep 29, 2025 | Molika Ashford Premium NEW YORK –Prenatal testing firm BillionToOne recently published the first data that explored

NEW YORK – Precision Epigenomics, a relatively recent entrant to the blood-based cancer screening field, continues to offer its EpiSeek multi-cancer

NEW YORK – Researchers are hopeful that the results of a study published this month, which demonstrated a sequencing methodology that can allow for

NEW YORK – Data presented from Grail's 36,000-person prospective trial Pathfinder 2 presented an even stronger picture of the firm's multi-cancer

NEW YORK – Exact Sciences on Monday reported on strategies for marketing and expanding access to new tests after significant developments in its blood-based cancer testing portfolio in recent months.